sotalol has been researched along with Myocardial Infarction in 74 studies
Sotalol: An adrenergic beta-antagonist that is used in the treatment of life-threatening arrhythmias.
sotalol : A sulfonamide that is N-phenylmethanesulfonamide in which the phenyl group is substituted at position 4 by a 1-hydroxy-2-(isopropylamino)ethyl group. It has both beta-adrenoreceptor blocking (Vaughan Williams Class II) and cardiac action potential duration prolongation (Vaughan Williams Class III) antiarrhythmic properties. It is used (usually as the hydrochloride salt) for the management of ventricular and supraventricular arrhythmias.
Myocardial Infarction: NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with a left ventricular ejection fraction of 40% or less and either a recent (6-42 days) myocardial infarction or symptomatic heart failure with a remote (> 42 days) myocardial infarction were randomly assigned d-sotalol (100 mg increased to 200 mg twice daily, if tolerated) or matching placebo twice daily." | 9.08 | Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. ( Camm, AJ; deRuyter, H; Friedman, PL; MacNeil, DJ; Pauls, JF; Pitt, B; Pratt, CM; Schwartz, PJ; Veltri, EP; Waldo, AL, 1996) |
| "Clinical trials have demonstrated a prophylactic role for aspirin in myocardial infarction and in unstable angina pectoris." | 9.07 | Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. ( Edvardsson, N; Jahnmatz, B; Juul-Möller, S; Omblus, R; Rosén, A; Sørensen, S, 1992) |
| " QTc dispersion was measured in 67 patients post myocardial infarction randomized to treatment with either sotalol or placebo." | 9.07 | Reduction in QT dispersion by sotalol following myocardial infarction. ( Campbell, RW; Day, CP; Matthews, J; McComb, JM, 1991) |
| "Thirty-five patients with suspected acute myocardial infarction were studied in a randomised controlled trial to determine whether the catecholamine response to myocardial infarction was altered by administration of the beta blocker, sotalol, given within six hours of the onset of chest pain." | 9.06 | The catecholamine response to acute myocardial infarction: effect of early administration of sotalol. ( Arnolda, L; McGrath, B; Saltups, A, 1986) |
| "In order to dissociate the Class III effects of sotalol on QT interval and arrhythmias from those of chronic beta-receptor blockade, we compared the effects of sotalol 160 mg b." | 9.06 | A comparison of the long-term effects of sotalol and atenolol on QT interval and arrhythmias after myocardial infarction. ( Alexopoulos, D; Cobbe, PC; Cobbe, SM; Johnston, J; McCaie, CP; Winner, SJ, 1988) |
| "In a multicentre double-blind randomised study, the effect of sotalol 320 mg once daily was compared with that of placebo in patients surviving an acute myocardial infarction." | 9.05 | Controlled trial of sotalol for one year after myocardial infarction. ( Jackson, FS; Julian, DG; Prescott, RJ; Szekely, P, 1982) |
| "We carried out a double-blind, randomized study, based at The Academic Department of Cardiology in Newcastle upon Tyne, to compare the effect of sotalol 320 mg once daily with that of placebo in patients from 20 hospitals who survived an acute myocardial infarction." | 9.05 | A controlled trial of sotalol for 1 year after myocardial infarction. ( Jackson, FS; Julian, DG; Prescott, RJ; Szekely, P, 1983) |
| "The aim of the present study was to characterize the influence of D,L-sotalol on arterial baroreflex sensitivity (BRS) which is generally considered as an estimate of vagal activity and has prognostic value in patients after myocardial infarction (MI)." | 7.71 | d,l-sotalol enhances baroreflex sensitivity in conscious rats surviving acute myocardial infarction. ( Haass, M; Krüger, C; Kübler, W; Landerer, V; Zugck, C, 2001) |
| " This study was performed to assess the effect of sotalol on the dispersion of refractoriness in experimental myocardial infarction." | 7.69 | Dispersion of ventricular refractoriness in experimental myocardial infarction: effect of sotalol. ( Borggrefe, M; Breithardt, G; Haverkamp, W; Hindricks, G; Lubiński, A; Shenasa, M; Vogt, B, 1994) |
| "The class III antiarrhythmics azimilide dihydrochloride and dl-sotalol were evaluated for ability to suppress induction of ventricular tachyarrhythmias (VT) in anesthetized, male mongrel dogs 4-6 days after surgical infarction of the left ventricle (LV) produced by ligation/reperfusion of the left anterior descending coronary artery." | 7.69 | Suppression of inducible ventricular arrhythmias by intravenous azimilide in dogs with previous myocardial infarction. ( Brooks, RR; Drexler, AP; Micklas, JM, 1996) |
| "The electrophysiologic and antiarrhythmic effects of ibutilide, sotalol, and encainide were compared in dogs 24 h after myocardial infarction." | 7.68 | Effects of ibutilide on spontaneous and induced ventricular arrhythmias in 24-hour canine myocardial infarction: a comparative study with sotalol and encainide. ( Brunden, MN; Buchanan, LV; Gibson, JK; Kabell, G; Turcotte, UM, 1992) |
| "The efficacy of oral sotalol in preventing sustained ventricular tachycardia induction by invasive electrophysiological testing was assessed in 22 patients (60 +/- 9 years) with prior myocardial infarction." | 7.68 | Efficacy and electrophysiologic effects of oral sotalol in patients with sustained ventricular tachycardia caused by coronary artery disease. ( Campa, MA; Dubuc, M; Kaltenbrunner, W; Kus, T; Nadeau, R; Shenasa, M, 1992) |
| "We explored the central hemodynamic responses to oral sotalol during dose titration in patients with ventricular arrhythmias who underwent programmed ventricular stimulation." | 7.68 | Effect of oral sotalol on systemic hemodynamics and programmed electrical stimulation in patients with ventricular arrhythmias and structural heart disease. ( Deitchman, D; Gomes, JA; Kukin, M; Pe, E; Stewart, D; Winters, SL, 1993) |
| "The electrophysiologic effects and antiarrhythmic efficacy of oral sotalol were investigated in 42 patients with coronary artery disease and prior myocardial infarction who presented with ventricular tachycardia (VT), ventricular fibrillation (VF) or syncope." | 7.67 | Usefulness of sotalol in suppressing ventricular tachycardia or ventricular fibrillation in patients with healed myocardial infarcts. ( Finkelstein, D; Garan, H; Kuchar, DL; McComb, J; McGovern, BA; Rottman, JN; Ruskin, JN; Venditti, FJ, 1989) |
| "In order to assess whether Sotalol is an effective drug in patients (pts) with life-threatening ventricular tachyarrhythmias, programmed ventricular stimulation (PVS) was performed in 30 pts with recurrent ventricular tachycardia (VT) or ventricular fibrillation (VF) after myocardial infarction." | 7.67 | [Antiarrhythmia effectiveness of oral sotalol in patients with coronary heart disease and ventricular tachycardias]. ( Klein, H; Lichtlen, PR; Trappe, HJ, 1987) |
| " Its short-term antiarrhythmic effects were compared with those of metoprolol, which has neither short-term class III nor membrane-stabilizing action, on reentrant ventricular arrhythmias produced by programmed stimulation in 17 conscious dogs 3 to 8 days after myocardial infarction." | 7.66 | Action of sotalol on potential reentrant pathways and ventricular tachyarrhythmias in conscious dogs in the late postmyocardial infarction phase. ( Brachmann, J; Cobbe, SM; Hoffman, E; Kübler, W; Ritzenhoff, A; Senges, J, 1983) |
| "Sotalol was administered to 10 patients over 12 hours by a continuous infusion including three different infusion rates." | 6.66 | Haemodynamic effects of intravenous sotalol in acute myocardial infarction. ( Aström, M; Edhag, O; Nyquist, O; Vallin, H, 1986) |
| "Sustained ventricular tachycardia was induced by programmed stimulation in dogs 4 days after left anterior coronary artery occlusion and reentrant circuits in the epicardial border zone (EBZ) mapped." | 5.32 | Beta receptor blockade potentiates the antiarrhythmic actions of d-sotalol on reentrant ventricular tachycardia in a canine model of myocardial infarction. ( Cabo, C; Coromilas, J; Kassotis, J; Sauberman, RB; Wit, AL, 2003) |
| "Sotalol was especially effective in reducing high grade arrhythmias (couplets, "R on T" VPCs)." | 5.27 | Long-term sotalol therapy in patients with ventricular arrhythmias. ( Mary-Rabine, L; Soumagne, D; Stiels, B, 1986) |
| "There was a strong trend towards lower mortality associated with the use of class I antiarrhythmic agents or sotalol in managing patients with atrial fibrillation after acute myocardial infarction." | 5.10 | Management and outcome of patients with atrial fibrillation during acute myocardial infarction: the GUSTO-III experience. Global use of strategies to open occluded coronary arteries. ( Califf, RM; Criger, DA; Ohman, EM; Topol, EJ; White, HD; Wilcox, RG; Wong, CK, 2002) |
| "Patients with a left ventricular ejection fraction of 40% or less and either a recent (6-42 days) myocardial infarction or symptomatic heart failure with a remote (> 42 days) myocardial infarction were randomly assigned d-sotalol (100 mg increased to 200 mg twice daily, if tolerated) or matching placebo twice daily." | 5.08 | Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. ( Camm, AJ; deRuyter, H; Friedman, PL; MacNeil, DJ; Pauls, JF; Pitt, B; Pratt, CM; Schwartz, PJ; Veltri, EP; Waldo, AL, 1996) |
| "The Survival With ORal D-sotalol (SWORD) trial tested the hypothesis that the prophylactic administration of oral d-sotalol would reduce total mortality in patients surviving myocardial infarction (MI) with a left ventricular ejection fraction (LVEF) of < or = 40%." | 5.08 | Mortality in the Survival With ORal D-sotalol (SWORD) trial: why did patients die? ( Camm, AJ; Cooper, W; Friedman, PL; MacNeil, DJ; Moulton, KM; Pitt, B; Pratt, CM; Schwartz, PJ; Veltri, EP; Waldo, AL, 1998) |
| " QTc dispersion was measured in 67 patients post myocardial infarction randomized to treatment with either sotalol or placebo." | 5.07 | Reduction in QT dispersion by sotalol following myocardial infarction. ( Campbell, RW; Day, CP; Matthews, J; McComb, JM, 1991) |
| "Clinical trials have demonstrated a prophylactic role for aspirin in myocardial infarction and in unstable angina pectoris." | 5.07 | Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. ( Edvardsson, N; Jahnmatz, B; Juul-Möller, S; Omblus, R; Rosén, A; Sørensen, S, 1992) |
| "In order to dissociate the Class III effects of sotalol on QT interval and arrhythmias from those of chronic beta-receptor blockade, we compared the effects of sotalol 160 mg b." | 5.06 | A comparison of the long-term effects of sotalol and atenolol on QT interval and arrhythmias after myocardial infarction. ( Alexopoulos, D; Cobbe, PC; Cobbe, SM; Johnston, J; McCaie, CP; Winner, SJ, 1988) |
| "Thirty-five patients with suspected acute myocardial infarction were studied in a randomised controlled trial to determine whether the catecholamine response to myocardial infarction was altered by administration of the beta blocker, sotalol, given within six hours of the onset of chest pain." | 5.06 | The catecholamine response to acute myocardial infarction: effect of early administration of sotalol. ( Arnolda, L; McGrath, B; Saltups, A, 1986) |
| "In a multicentre double-blind randomised study, the effect of sotalol 320 mg once daily was compared with that of placebo in patients surviving an acute myocardial infarction." | 5.05 | Controlled trial of sotalol for one year after myocardial infarction. ( Jackson, FS; Julian, DG; Prescott, RJ; Szekely, P, 1982) |
| "We carried out a double-blind, randomized study, based at The Academic Department of Cardiology in Newcastle upon Tyne, to compare the effect of sotalol 320 mg once daily with that of placebo in patients from 20 hospitals who survived an acute myocardial infarction." | 5.05 | A controlled trial of sotalol for 1 year after myocardial infarction. ( Jackson, FS; Julian, DG; Prescott, RJ; Szekely, P, 1983) |
| "Recently completed Beta-Blocker Heart Attack Trial in which propranolol was administered to patients following an acute myocardial infarction resulted in a 26% decrease in total mortality and a 23% decrease in total coronary events in the propranolol-treated patients as compared to the placebo patients during the average follow-up of 25 months." | 5.05 | The Beta-Blocker Heart Attack Trial in perspective. ( Goldstein, S, 1983) |
| "The aim of the present study was to characterize the influence of D,L-sotalol on arterial baroreflex sensitivity (BRS) which is generally considered as an estimate of vagal activity and has prognostic value in patients after myocardial infarction (MI)." | 3.71 | d,l-sotalol enhances baroreflex sensitivity in conscious rats surviving acute myocardial infarction. ( Haass, M; Krüger, C; Kübler, W; Landerer, V; Zugck, C, 2001) |
| " A total of 152 patients with remote myocardial infarction and documented ventricular tachycardia (VT) or ventricular fibrillation (VF) underwent coronary angiography and programmed ventricular stimulation before and after oral administration of d,l-sotalol (240-640 mg/day)." | 3.70 | Infarct related artery patency: relation to serial electropharmacological studies and outcome in patients with previous myocardial infarction and ventricular tachyarrhythmias. ( Borggrefe, M; Breithardt, G; Haverkamp, W; Hoppe, UC, 2000) |
| " This study was performed to assess the effect of sotalol on the dispersion of refractoriness in experimental myocardial infarction." | 3.69 | Dispersion of ventricular refractoriness in experimental myocardial infarction: effect of sotalol. ( Borggrefe, M; Breithardt, G; Haverkamp, W; Hindricks, G; Lubiński, A; Shenasa, M; Vogt, B, 1994) |
| "The class III antiarrhythmics azimilide dihydrochloride and dl-sotalol were evaluated for ability to suppress induction of ventricular tachyarrhythmias (VT) in anesthetized, male mongrel dogs 4-6 days after surgical infarction of the left ventricle (LV) produced by ligation/reperfusion of the left anterior descending coronary artery." | 3.69 | Suppression of inducible ventricular arrhythmias by intravenous azimilide in dogs with previous myocardial infarction. ( Brooks, RR; Drexler, AP; Micklas, JM, 1996) |
| "To evaluate the antiarrhythmic efficacy of l-sotalol and bisoprolol on inducible ventricular arrhythmias, conscious dogs with 4- to 8-day-old myocardial infarction were studied by programmed electrical stimulation." | 3.69 | Electrophysiological mechanisms of action of the levorotatory isomer of sotalol in a canine infarct model of inducible ventricular tachycardia: comparison with the beta-1 receptor antagonist bisoprolol. ( Aidonidis, I; Brachmann, J; Hilbel, T; Kuebler, W; Rizos, I, 1994) |
| "The efficacy of oral sotalol in preventing sustained ventricular tachycardia induction by invasive electrophysiological testing was assessed in 22 patients (60 +/- 9 years) with prior myocardial infarction." | 3.68 | Efficacy and electrophysiologic effects of oral sotalol in patients with sustained ventricular tachycardia caused by coronary artery disease. ( Campa, MA; Dubuc, M; Kaltenbrunner, W; Kus, T; Nadeau, R; Shenasa, M, 1992) |
| "We explored the central hemodynamic responses to oral sotalol during dose titration in patients with ventricular arrhythmias who underwent programmed ventricular stimulation." | 3.68 | Effect of oral sotalol on systemic hemodynamics and programmed electrical stimulation in patients with ventricular arrhythmias and structural heart disease. ( Deitchman, D; Gomes, JA; Kukin, M; Pe, E; Stewart, D; Winters, SL, 1993) |
| "The electrophysiologic and antiarrhythmic effects of ibutilide, sotalol, and encainide were compared in dogs 24 h after myocardial infarction." | 3.68 | Effects of ibutilide on spontaneous and induced ventricular arrhythmias in 24-hour canine myocardial infarction: a comparative study with sotalol and encainide. ( Brunden, MN; Buchanan, LV; Gibson, JK; Kabell, G; Turcotte, UM, 1992) |
| "Eighteen patients with sustained ventricular tachycardia underwent serial electrophysiological studies to establish the therapeutic efficacy of sotalol as compared to other available anti-arrhythmic agents." | 3.67 | Contribution of delayed ventricular repolarization to the anti-arrhythmic efficacy of sotalol. ( Brachmann, J; Cobbe, SM; Czygan, E; Jauernig, R; Kübler, W; Lengfelder, W; Rizos, I; Senges, J, 1985) |
| "5 V, 750 ms) or programmed ventricular stimulation, creation of a small myocardial infarction, and application of antiarrhythmic drugs (ajmalin, lidocaine, sotalol)." | 3.67 | Acute induction of sustained ventricular tachycardia: a new porcine model. ( Lüderitz, B; Nitsch, J; Schmid, C, 1989) |
| "The electrophysiologic effects and antiarrhythmic efficacy of oral sotalol were investigated in 42 patients with coronary artery disease and prior myocardial infarction who presented with ventricular tachycardia (VT), ventricular fibrillation (VF) or syncope." | 3.67 | Usefulness of sotalol in suppressing ventricular tachycardia or ventricular fibrillation in patients with healed myocardial infarcts. ( Finkelstein, D; Garan, H; Kuchar, DL; McComb, J; McGovern, BA; Rottman, JN; Ruskin, JN; Venditti, FJ, 1989) |
| "In order to assess whether Sotalol is an effective drug in patients (pts) with life-threatening ventricular tachyarrhythmias, programmed ventricular stimulation (PVS) was performed in 30 pts with recurrent ventricular tachycardia (VT) or ventricular fibrillation (VF) after myocardial infarction." | 3.67 | [Antiarrhythmia effectiveness of oral sotalol in patients with coronary heart disease and ventricular tachycardias]. ( Klein, H; Lichtlen, PR; Trappe, HJ, 1987) |
| " Its short-term antiarrhythmic effects were compared with those of metoprolol, which has neither short-term class III nor membrane-stabilizing action, on reentrant ventricular arrhythmias produced by programmed stimulation in 17 conscious dogs 3 to 8 days after myocardial infarction." | 3.66 | Action of sotalol on potential reentrant pathways and ventricular tachyarrhythmias in conscious dogs in the late postmyocardial infarction phase. ( Brachmann, J; Cobbe, SM; Hoffman, E; Kübler, W; Ritzenhoff, A; Senges, J, 1983) |
| "Sudden cardiac death was observed in 16 patients, 8 patients in each group." | 2.72 | Determinants of sudden cardiac death in patients with persistent atrial fibrillation in the rate control versus electrical cardioversion (RACE) study. ( Crijns, HJ; Hagens, VE; Rienstra, M; Van Gelder, IC; Van Veldhuisen, DJ, 2006) |
| "Sotalol was administered to 10 patients over 12 hours by a continuous infusion including three different infusion rates." | 2.66 | Haemodynamic effects of intravenous sotalol in acute myocardial infarction. ( Aström, M; Edhag, O; Nyquist, O; Vallin, H, 1986) |
| " In situations where ventricular anti-arrhythmic therapy is deemed necessary, especially if long-term use is considered, sotalol seems to be the agent of choice." | 2.65 | The efficacy of sotalol in suppressing ventricular ectopic beats. ( Cartoon, J; Goldman, aP; Myburgh, DP; Schamroth, JM, 1979) |
| "Amiodarone has been demonstrated to be more efficacious than propafenone or sotalol in the Canadian Trial of Atrial Fibrillation." | 2.42 | Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials. ( Bhatta, L; Hynes, J; Khan, M; Luck, J; Naccarelli, GV; Samii, S; Wolbrette, DL, 2003) |
| "Sudden cardiac death is a prominent feature of the natural history of heart disease." | 2.41 | Overview of randomized trials of antiarrhythmic drugs and devices for the prevention of sudden cardiac death. ( Heidenreich, PA; Hlatky, MA; Keeffe, B; McDonald, KM, 2002) |
| "Torsades de pointes is the classic form of proarrhythmia observed during therapy with any drug that prolongs repolarization, for example, the class III agents." | 2.40 | Proarrhythmia with class III antiarrhythmic drugs: types, risks, and management. ( Hohnloser, SH, 1997) |
| "Sotalol is a novel antiarrhythmic agent combining beta-adrenergic-antagonist actions with the ability to increase cardiac repolarization and refractoriness." | 2.39 | Sotalol. ( Hohnloser, SH; Woosley, RL, 1994) |
| "Sustained ventricular tachycardia was induced by programmed stimulation in dogs 4 days after left anterior coronary artery occlusion and reentrant circuits in the epicardial border zone (EBZ) mapped." | 1.32 | Beta receptor blockade potentiates the antiarrhythmic actions of d-sotalol on reentrant ventricular tachycardia in a canine model of myocardial infarction. ( Cabo, C; Coromilas, J; Kassotis, J; Sauberman, RB; Wit, AL, 2003) |
| "Occurrence rates of arrhythmias treated with drugs tested for efficacy either by suppression of inducible arrhythmias or by suppression of spontaneous ectopy were higher and equivalent for both testing methods." | 1.29 | From first class to third class: recent upheaval in antiarrhythmic therapy--lessons from clinical trials. ( Lazzara, R, 1996) |
| "Slowing of ventricular tachycardia rate and changes in morphology may have implications in patients receiving implantable cardioverter-defibrillators or those undergoing ablative procedures." | 1.29 | Clinical implications of pleomorphic ventricular tachycardias on oral sotalol therapy. ( Borggrefe, M; Breithardt, G; Chen, X; Haverkamp, W; Hindricks, G; Lubinski, A; Reisinger, J; Shenasa, M, 1995) |
| "Mexiletine was recently shown to antagonize the effects of sotalol on repolarization of canine Purkinje fibers." | 1.29 | Antiarrhythmic effect of a sotalol-mexiletine combination on induced ventricular tachycardia in dogs. ( Cheymol, G; Chézalviel, F; Davy, JM; Guhennec, C; Jagueux, M; Poirier, JM; Simandoux, V; Vernhet, L; Weissenburger, J, 1993) |
| "Disopyramide was only modestly active, while flecainide and encainide had the least favorable profiles of effect in suppressing re-entry arrhythmias in this model." | 1.27 | Assessment of drug effects on spontaneous and induced ventricular arrhythmias in a 24-h canine infarction model. ( Gomoll, AW, 1987) |
| "Sotalol was especially effective in reducing high grade arrhythmias (couplets, "R on T" VPCs)." | 1.27 | Long-term sotalol therapy in patients with ventricular arrhythmias. ( Mary-Rabine, L; Soumagne, D; Stiels, B, 1986) |
| "Correspondingly, ventricular arrhythmias and fibrillation were almost completely prevented by metoprolol, d-sotalol or verapamil, but increased by lidocaine." | 1.27 | Comparative investigations on the antiarrhythmic and electrophysiologic effects of class I-IV antiarrhythmic agents following acute coronary artery occlusion. ( Gülker, H; Haverkamp, W; Hindricks, G; Thale, J, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 31 (41.89) | 18.7374 |
| 1990's | 31 (41.89) | 18.2507 |
| 2000's | 12 (16.22) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Johnson, RE | 1 |
| Baizman, ER | 1 |
| Becker, C | 1 |
| Bohnet, EA | 1 |
| Bell, RH | 1 |
| Birsner, NC | 1 |
| Busacca, CA | 1 |
| Carabateas, PM | 1 |
| Chadwick, CC | 1 |
| Gruett, MD | 1 |
| Andersen, SS | 1 |
| Hansen, ML | 1 |
| Gislason, GH | 1 |
| Folke, F | 1 |
| Schramm, TK | 1 |
| Fosbøl, E | 1 |
| Sørensen, R | 1 |
| Rasmussen, S | 1 |
| Abildstrøm, SZ | 1 |
| Madsen, M | 1 |
| Køber, L | 1 |
| Torp-Pedersen, C | 1 |
| Spivack, C | 1 |
| Heidenreich, PA | 1 |
| Keeffe, B | 1 |
| McDonald, KM | 1 |
| Hlatky, MA | 1 |
| Wong, CK | 1 |
| White, HD | 1 |
| Wilcox, RG | 1 |
| Criger, DA | 1 |
| Califf, RM | 1 |
| Topol, EJ | 1 |
| Ohman, EM | 1 |
| Naccarelli, GV | 1 |
| Wolbrette, DL | 1 |
| Khan, M | 1 |
| Bhatta, L | 1 |
| Hynes, J | 1 |
| Samii, S | 1 |
| Luck, J | 1 |
| Pratt, CM | 4 |
| Kassotis, J | 1 |
| Sauberman, RB | 1 |
| Cabo, C | 1 |
| Wit, AL | 1 |
| Coromilas, J | 1 |
| Hohnloser, SH | 3 |
| Dorian, P | 1 |
| Roberts, R | 1 |
| Gent, M | 1 |
| Israel, CW | 1 |
| Fain, E | 1 |
| Champagne, J | 1 |
| Connolly, SJ | 1 |
| Hagens, VE | 1 |
| Rienstra, M | 1 |
| Van Veldhuisen, DJ | 1 |
| Crijns, HJ | 1 |
| Van Gelder, IC | 1 |
| Patterson, E | 1 |
| Lynch, JJ | 1 |
| Lucchesi, BR | 1 |
| Julian, DG | 2 |
| Prescott, RJ | 2 |
| Jackson, FS | 2 |
| Szekely, P | 2 |
| Staessen, J | 1 |
| Bulpitt, C | 1 |
| Cattaert, A | 1 |
| Fagard, R | 1 |
| Vanhees, L | 1 |
| Amery, A | 1 |
| Weisswange, A | 1 |
| Goldstein, S | 1 |
| Frishman, WH | 2 |
| Furberg, CD | 2 |
| Friedewald, WT | 2 |
| Tomov, I | 1 |
| Cobbe, SM | 4 |
| Hoffman, E | 1 |
| Ritzenhoff, A | 1 |
| Brachmann, J | 7 |
| Kübler, W | 6 |
| Senges, J | 3 |
| Burckhardt, D | 1 |
| White, RA | 1 |
| Hoffmann, A | 1 |
| Blümchen, G | 1 |
| Esche, HH | 1 |
| Chézalviel, F | 1 |
| Weissenburger, J | 1 |
| Guhennec, C | 1 |
| Jagueux, M | 1 |
| Davy, JM | 1 |
| Vernhet, L | 1 |
| Simandoux, V | 1 |
| Poirier, JM | 1 |
| Cheymol, G | 1 |
| Kidwell, GA | 1 |
| Gonzalez, MD | 1 |
| Waldo, AL | 3 |
| Camm, AJ | 3 |
| deRuyter, H | 2 |
| Freidman, PL | 1 |
| MacNeil, DJ | 3 |
| Pitt, B | 3 |
| Rodda, BE | 1 |
| Schwartz, PJ | 4 |
| Reisinger, J | 1 |
| Shenasa, M | 3 |
| Lubinski, A | 2 |
| Hindricks, G | 3 |
| Haverkamp, W | 4 |
| Chen, X | 1 |
| Breithardt, G | 3 |
| Borggrefe, M | 3 |
| Vogt, B | 1 |
| Aidonidis, I | 1 |
| Rizos, I | 2 |
| Hilbel, T | 2 |
| Kuebler, W | 1 |
| Boersma, L | 1 |
| Brugada, J | 1 |
| Abdollah, H | 1 |
| Kirchhof, C | 1 |
| Allessie, M | 1 |
| Woosley, RL | 1 |
| Winters, SL | 1 |
| Kukin, M | 1 |
| Pe, E | 1 |
| Stewart, D | 1 |
| Deitchman, D | 1 |
| Gomes, JA | 1 |
| Sanderson, J | 1 |
| Friedman, PL | 2 |
| Pauls, JF | 1 |
| Veltri, EP | 2 |
| Singh, BN | 2 |
| Lazzara, R | 1 |
| Drexler, AP | 1 |
| Micklas, JM | 1 |
| Brooks, RR | 1 |
| Scholz, H | 1 |
| de Meester, A | 1 |
| Chaudron, JM | 1 |
| de Roy, L | 1 |
| Freigang, KD | 1 |
| Bauer, A | 1 |
| Becker, R | 1 |
| Senges, JC | 1 |
| Kraft, P | 1 |
| Schoels, W | 1 |
| Cooper, W | 1 |
| Moulton, KM | 1 |
| Marschang, H | 1 |
| Schöls, W | 1 |
| Karolyi, L | 1 |
| Beyer, T | 2 |
| Laurenzi, F | 1 |
| Avella, A | 1 |
| Adinolfi, E | 1 |
| Dini, P | 1 |
| Hoppe, UC | 1 |
| Krüger, C | 1 |
| Zugck, C | 1 |
| Landerer, V | 1 |
| Haass, M | 1 |
| Myburgh, DP | 1 |
| Goldman, aP | 1 |
| Cartoon, J | 1 |
| Schamroth, JM | 1 |
| Juul-Möller, S | 1 |
| Edvardsson, N | 1 |
| Jahnmatz, B | 1 |
| Rosén, A | 1 |
| Sørensen, S | 1 |
| Omblus, R | 1 |
| Buchanan, LV | 1 |
| Kabell, G | 1 |
| Turcotte, UM | 1 |
| Brunden, MN | 1 |
| Gibson, JK | 1 |
| Schmitt, C | 1 |
| Karch, M | 1 |
| Montero, M | 1 |
| Kus, T | 1 |
| Campa, MA | 1 |
| Nadeau, R | 1 |
| Dubuc, M | 1 |
| Kaltenbrunner, W | 1 |
| Day, CP | 2 |
| McComb, JM | 2 |
| Matthews, J | 1 |
| Campbell, RW | 2 |
| Aström, M | 2 |
| Edhag, O | 2 |
| Nyquist, O | 2 |
| Vallin, H | 2 |
| Mary-Rabine, L | 1 |
| Soumagne, D | 1 |
| Stiels, B | 1 |
| Alexopoulos, D | 1 |
| Winner, SJ | 1 |
| McCaie, CP | 1 |
| Cobbe, PC | 1 |
| Johnston, J | 1 |
| Kuchar, DL | 1 |
| Garan, H | 1 |
| Venditti, FJ | 1 |
| Finkelstein, D | 1 |
| Rottman, JN | 1 |
| McComb, J | 1 |
| McGovern, BA | 1 |
| Ruskin, JN | 1 |
| Schmid, C | 1 |
| Nitsch, J | 1 |
| Lüderitz, B | 1 |
| Gomoll, AW | 1 |
| Lloyd, EA | 1 |
| Charles, RG | 1 |
| Gordon, GD | 1 |
| Adams, CM | 1 |
| Mabin, TA | 1 |
| Commerford, PJ | 1 |
| Opie, LH | 1 |
| Thale, J | 1 |
| Gülker, H | 1 |
| McGrath, B | 1 |
| Arnolda, L | 1 |
| Saltups, A | 1 |
| Ramsdale, DR | 1 |
| Peterson, C | 1 |
| Trappe, HJ | 1 |
| Klein, H | 1 |
| Lichtlen, PR | 1 |
| Gao, TL | 1 |
| Wehr, M | 1 |
| Lengfelder, W | 1 |
| Jauernig, R | 1 |
| Czygan, E | 1 |
| Mulholland, HC | 1 |
| Pantridge, JF | 1 |
| Gettes, LS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| aMsa and amiOdarone Study in cArdiaC Arrest[NCT04997980] | 500 participants (Anticipated) | Observational | 2015-01-01 | Recruiting | |||
| [NCT00257959] | Phase 4 | 400 participants | Interventional | 2001-01-31 | Completed | ||
| [NCT00000492] | Phase 3 | 0 participants | Interventional | 1977-09-30 | Completed | ||
| Heart Rate Lowering Efficacy and Respiratory Safety of Ivabradine in Patients With Obstructive Airway Disease[NCT01365286] | Phase 4 | 40 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| Catheter Ablation for Ventricular Tachycardia in Patients With an Implantable Cardioverter Defibrillator (CALYPSO) PILOT TRIAL[NCT01576042] | 27 participants (Actual) | Interventional | 2012-05-31 | Terminated (stopped due to Main objectives of the study were met; consensus among investigators that continuing the study would not add new information beyond that already learned.) | |||
| Safety Assessment for Sotalol Protocol in Outpatient Unit[NCT05418036] | Phase 4 | 110 participants (Anticipated) | Interventional | 2020-10-26 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Records participants hospitalized for VT during the study (NCT01576042)
Timeframe: Baseline, 6 months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 5 |
| Antiarrhythmic Medication | 7 |
Records participants who completed Month 3 Follow-Up Visit (NCT01576042)
Timeframe: 3 months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 11 |
| Antiarrhythmic Medication | 12 |
Records participants who completed Month 6 Follow-Up Visit (NCT01576042)
Timeframe: 6 Months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 7 |
| Antiarrhythmic Medication | 10 |
Records participants who had at least one of the efficacy outcome measurement (including death, hospitalization due to VT) (NCT01576042)
Timeframe: 6 Months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 11 |
| Antiarrhythmic Medication | 14 |
Records participants who received study randomized treatment during the study (NCT01576042)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 11 |
| Antiarrhythmic Medication | 14 |
Records participants who only received study treatment as randomized during the entire study (NCT01576042)
Timeframe: 6 month
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 6 |
| Antiarrhythmic Medication | 13 |
Records participants who received study treatment as randomized and later switched to other treatment arm during the study (NCT01576042)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 5 |
| Antiarrhythmic Medication | 1 |
Days from the date of the first study treatment to the date of first ICD recurrent therapy for VT. (NCT01576042)
Timeframe: Baseline, 6 months
| Intervention | Days (Mean) |
|---|---|
| Catheter Ablation | 70.1 |
| Antiarrhythmic Medication | 78.7 |
11 reviews available for sotalol and Myocardial Infarction
| Article | Year |
|---|---|
Overview of randomized trials of antiarrhythmic drugs and devices for the prevention of sudden cardiac death.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillators, Implantable; Femal | 2002 |
Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Australia; Canada; Controlled Clinical Tria | 2003 |
Pure class III agents for prevention of sudden cardiac death.
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Comorbidity; Death, Sudden, C | 2003 |
Beta-adrenergic blockade for survivors of acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Alprenolol; Arrhythmias, Cardiac; Clinical Trials as Topic; Coron | 1984 |
The use of beta-adrenergic blocking drugs in patients with myocardial infarction.
Topics: Adrenergic beta-Antagonists; Alprenolol; Angina Pectoris; Atenolol; Clinical Trials as Topic; Humans | 1984 |
[Therapeutic value of the long-term administration of beta-adrenergic blockaders after myocardial infarct].
Topics: Adrenergic beta-Antagonists; Alprenolol; Clinical Trials as Topic; Humans; Metoprolol; Myocardial In | 1984 |
Sotalol.
Topics: Action Potentials; Animals; Electrocardiography; Electrophysiology; Humans; Myocardial Contraction; | 1994 |
[Ventricular cardiac arrhythmias. New anti-arrhythmia agents].
Topics: Amiodarone; Anti-Arrhythmia Agents; Clinical Trials as Topic; Electrocardiography; Heart Conduction | 1996 |
Proarrhythmia with class III antiarrhythmic drugs: types, risks, and management.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Heart Conduction System; Humans; Myocardia | 1997 |
Beta adrenergic blocking drugs in the treatment of cardiac arrhythmias.
Topics: Adrenergic beta-Antagonists; Alprenolol; Arrhythmia, Sinus; Arrhythmias, Cardiac; Atrial Fibrillatio | 1970 |
Anti-arrhythmic actions of -adrenergic receptor antagonists: review of fundamental aspects.
Topics: Action Potentials; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Animals; Arrhythmias, Card | 1972 |
23 trials available for sotalol and Myocardial Infarction
| Article | Year |
|---|---|
Management and outcome of patients with atrial fibrillation during acute myocardial infarction: the GUSTO-III experience. Global use of strategies to open occluded coronary arteries.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Female; Hospit | 2002 |
Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bisoprol | 2006 |
Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bisoprol | 2006 |
Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bisoprol | 2006 |
Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bisoprol | 2006 |
Determinants of sudden cardiac death in patients with persistent atrial fibrillation in the rate control versus electrical cardioversion (RACE) study.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2006 |
Controlled trial of sotalol for one year after myocardial infarction.
Topics: Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; | 1982 |
Secondary prevention with beta-adrenoceptor blockers in post-myocardial infarction patients.
Topics: Adrenergic beta-Antagonists; Clinical Trials as Topic; Double-Blind Method; Humans; Metoprolol; Myoc | 1982 |
[Improved prognosis using beta blockers after myocardial infarct?].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Clinical Trials as Topic; Female; Humans; Male; Metoprolol | 1984 |
The Beta-Blocker Heart Attack Trial in perspective.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Arrhythmias, Cardiac; Clinical Trials as Topic; Death, Sud | 1983 |
Beta-adrenergic blockade for survivors of acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Alprenolol; Arrhythmias, Cardiac; Clinical Trials as Topic; Coron | 1984 |
The use of beta-adrenergic blocking drugs in patients with myocardial infarction.
Topics: Adrenergic beta-Antagonists; Alprenolol; Angina Pectoris; Atenolol; Clinical Trials as Topic; Humans | 1984 |
[Therapeutic value of the long-term administration of beta-adrenergic blockaders after myocardial infarct].
Topics: Adrenergic beta-Antagonists; Alprenolol; Clinical Trials as Topic; Humans; Metoprolol; Myocardial In | 1984 |
A controlled trial of sotalol for 1 year after myocardial infarction.
Topics: Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Humans; Middle Aged; Myocardial Infarcti | 1983 |
Survival with oral d-sotalol in patients with left ventricular dysfunction after myocardial infarction: rationale, design, and methods (the SWORD trial).
Topics: Administration, Oral; Adolescent; Adult; Double-Blind Method; Female; Follow-Up Studies; Humans; Mal | 1995 |
Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol.
Topics: Administration, Oral; Anti-Arrhythmia Agents; Double-Blind Method; Female; Humans; Male; Middle Aged | 1996 |
[Prevention of sudden death in myocardial infarct: do experimental results help to understand the clinical reality? The case of the clinical trial SWORD (Survival With ORal D-sotalol)].
Topics: Acute Disease; Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Drug Therapy, Combination; Femal | 1996 |
Mortality in the Survival With ORal D-sotalol (SWORD) trial: why did patients die?
Topics: Administration, Oral; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Female; Humans; Male; Middle Age | 1998 |
The efficacy of sotalol in suppressing ventricular ectopic beats.
Topics: Adult; Aged; Arrhythmias, Cardiac; Clinical Trials as Topic; Double-Blind Method; Humans; Male; Midd | 1979 |
Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group.
Topics: Aged; Angina Pectoris; Aspirin; Double-Blind Method; Female; Hemorrhage; Humans; Male; Myocardial In | 1992 |
Reduction in QT dispersion by sotalol following myocardial infarction.
Topics: Arrhythmias, Cardiac; Double-Blind Method; Electrocardiography; Female; Follow-Up Studies; Humans; M | 1991 |
Electrophysiological effects of intravenous sotalol in acute myocardial infarction: a double-blind placebo-controlled study.
Topics: Arrhythmias, Cardiac; Atrioventricular Node; Clinical Trials as Topic; Double-Blind Method; Electroc | 1990 |
A comparison of the long-term effects of sotalol and atenolol on QT interval and arrhythmias after myocardial infarction.
Topics: Adult; Aged; Arrhythmias, Cardiac; Atenolol; Cardiac Complexes, Premature; Clinical Trials as Topic; | 1988 |
Beta-blockade by sotalol in early myocardial infarction decreases ventricular arrhythmias without increasing left ventricular volume.
Topics: Adult; Aged; Arrhythmias, Cardiac; Clinical Trials as Topic; Female; Heart Ventricles; Hemodynamics; | 1988 |
Haemodynamic effects of intravenous sotalol in acute myocardial infarction.
Topics: Aged; Clinical Trials as Topic; Creatine Kinase; Double-Blind Method; Electrocardiography; Hemodynam | 1986 |
The catecholamine response to acute myocardial infarction: effect of early administration of sotalol.
Topics: Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Drug Administration Schedule; Epineph | 1986 |
43 other studies available for sotalol and Myocardial Infarction
| Article | Year |
|---|---|
4,5-Dihydro-1-phenyl-1H-2,4-benzodiazepines: novel antiarrhythmic agents.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Benzodiazepines; Cats; Disease Models, Animal | 1993 |
Mortality and reinfarction among patients using different beta-blockers for secondary prevention after a myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Bisoprolol; Female; Humans; Kaplan-Meier Estimate; Male | 2009 |
Implantable cardiac defibrillators.
Topics: Amiodarone; Anti-Arrhythmia Agents; Combined Modality Therapy; Defibrillators, Implantable; Humans; | 2002 |
Beta receptor blockade potentiates the antiarrhythmic actions of d-sotalol on reentrant ventricular tachycardia in a canine model of myocardial infarction.
Topics: Adrenergic beta-Antagonists; Animals; Anti-Arrhythmia Agents; Dogs; Drug Synergism; Electrocardiogra | 2003 |
Antiarrhythmic and antifibrillatory actions of the beta adrenergic receptor antagonist, dl-sotalol.
Topics: Animals; Arrhythmias, Cardiac; Disease Models, Animal; Dogs; Electric Stimulation; Electrocardiograp | 1984 |
Action of sotalol on potential reentrant pathways and ventricular tachyarrhythmias in conscious dogs in the late postmyocardial infarction phase.
Topics: Action Potentials; Animals; Consciousness; Dogs; Electrocardiography; Heart Conduction System; Metop | 1983 |
Replacement of amiodarone by sotalol for repetitive ventricular premature beats.
Topics: Aged; Amiodarone; Arrhythmias, Cardiac; Benzofurans; Female; Humans; Male; Middle Aged; Myocardial I | 1984 |
[Chronic administration of beta blocking agents: left ventricular hemodynamics in myocardial infarctions during exercise (author's transl)].
Topics: Adult; Angina Pectoris; Cardiac Catheterization; Electrocardiography; Heart Ventricles; Hemodynamics | 1981 |
Antiarrhythmic effect of a sotalol-mexiletine combination on induced ventricular tachycardia in dogs.
Topics: Animals; Coronary Vessels; Dogs; Drug Combinations; Electric Stimulation; Electrocardiography; Elect | 1993 |
Effects of flecainide and D-sotalol on myocardial conduction and refractoriness: relation to antiarrhythmic and proarrhythmic drug effects.
Topics: Animals; Arrhythmias, Cardiac; Dogs; Electric Stimulation; Electrocardiography; Electrophysiology; F | 1993 |
Clinical implications of pleomorphic ventricular tachycardias on oral sotalol therapy.
Topics: Administration, Oral; Adult; Aged; Cardiac Pacing, Artificial; Coronary Disease; Electrocardiography | 1995 |
Dispersion of ventricular refractoriness in experimental myocardial infarction: effect of sotalol.
Topics: Animals; Cardiac Pacing, Artificial; Dogs; Female; Male; Myocardial Infarction; Refractory Period, E | 1994 |
Electrophysiological mechanisms of action of the levorotatory isomer of sotalol in a canine infarct model of inducible ventricular tachycardia: comparison with the beta-1 receptor antagonist bisoprolol.
Topics: Animals; Bisoprolol; Disease Models, Animal; Dogs; Electric Stimulation; Electrocardiography; Female | 1994 |
Effects of heptanol, class Ic, and class III drugs on reentrant ventricular tachycardia. Importance of the excitable gap for the inducibility of double-wave reentry.
Topics: Alcohols; Animals; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Electrocardiography; Estrenes | 1994 |
Effect of oral sotalol on systemic hemodynamics and programmed electrical stimulation in patients with ventricular arrhythmias and structural heart disease.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Arrhythmias, Cardiac; Cardiac Pacing, Artifici | 1993 |
Class III Antiarrhythmics: put to the SWORD?
Topics: Action Potentials; Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Huma | 1996 |
The SWORD of Damocles.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Humans; Myocardial Infarction; Randomized | 1996 |
The coming of age of the class III antiarrhythmic principle: retrospective and future trends.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; Electrophysiolog | 1996 |
From first class to third class: recent upheaval in antiarrhythmic therapy--lessons from clinical trials.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Heart Conduct | 1996 |
Suppression of inducible ventricular arrhythmias by intravenous azimilide in dogs with previous myocardial infarction.
Topics: Adrenergic beta-Antagonists; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Calcium Channel | 1996 |
Usefulness of isoproterenol in the induction of clinical sustained ventricular tachycardia during electrophysiological study.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Aged; Atenolol; Cardiac Pacing, Artificial; E | 1997 |
Differential effects of d-sotalol on normal and infarcted myocardium: an experimental study using epicardial mapping.
Topics: Animals; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Dogs; Electrocardiography; Electrophysi | 1997 |
Differential effects of d-sotalol on subendocardial Purkinje myocytes isolated from normal or 10 to 14 days postinfarction canine hearts: role of extracellular potassium concentration.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Cells, Cultured; Dogs; Heart; Myocardial Infarct | 1998 |
[Role of electrophysiology in the prognosis and therapy of cardiomyopathies].
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiomyopath | 1999 |
Infarct related artery patency: relation to serial electropharmacological studies and outcome in patients with previous myocardial infarction and ventricular tachyarrhythmias.
Topics: Aged; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Coronary Angiography; Death, Sudden, Cardi | 2000 |
Which beta-blocker?
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Arrhythmias, Cardiac; Bradycardia; Heart Failure; Huma | 2001 |
d,l-sotalol enhances baroreflex sensitivity in conscious rats surviving acute myocardial infarction.
Topics: Acute Disease; Adrenergic beta-Antagonists; Analysis of Variance; Animals; Baroreflex; Blood Pressur | 2001 |
Effects of ibutilide on spontaneous and induced ventricular arrhythmias in 24-hour canine myocardial infarction: a comparative study with sotalol and encainide.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Dogs; Electrocardiography; Encainide; Hemodyn | 1992 |
Sotalol exhibits reverse use-dependent action on monophasic action potentials in normal but not in infarcted canine ventricular myocardium.
Topics: Action Potentials; Animals; Dogs; Electrocardiography; Heart; Heart Conduction System; Myocardial In | 1992 |
Efficacy and electrophysiologic effects of oral sotalol in patients with sustained ventricular tachycardia caused by coronary artery disease.
Topics: Administration, Oral; Adult; Aged; Cardiac Pacing, Artificial; Coronary Artery Disease; Electrocardi | 1992 |
QT dispersion: an indication of arrhythmia risk in patients with long QT intervals.
Topics: Adolescent; Adult; Arrhythmias, Cardiac; Child; Electrocardiography; Female; Heart; Heart Rate; Huma | 1990 |
Long-term sotalol therapy in patients with ventricular arrhythmias.
Topics: Aged; Angina Pectoris; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Cardiomyopathy, Dilated; | 1986 |
Usefulness of sotalol in suppressing ventricular tachycardia or ventricular fibrillation in patients with healed myocardial infarcts.
Topics: Aged; Coronary Disease; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Middle Aged; M | 1989 |
Acute induction of sustained ventricular tachycardia: a new porcine model.
Topics: Animals; Disease Models, Animal; Electric Stimulation; Electrocardiography; Heart; Heart Ventricles; | 1989 |
Assessment of drug effects on spontaneous and induced ventricular arrhythmias in a 24-h canine infarction model.
Topics: Anilides; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Disopyramide; Dogs; Electrocardiogr | 1987 |
Comparative investigations on the antiarrhythmic and electrophysiologic effects of class I-IV antiarrhythmic agents following acute coronary artery occlusion.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Coronary Disease; Dogs; Female; Heart Conduct | 1987 |
Repeated warnings re repeated measures.
Topics: Catecholamines; Humans; Myocardial Infarction; Sotalol | 1987 |
Successful termination of combined rapid atrial flutter/fibrillation and ventricular tachycardia by intravenous sotalol.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Atrial Flutter; Electrocardiography; Humans; Infusions | 1987 |
[Antiarrhythmia effectiveness of oral sotalol in patients with coronary heart disease and ventricular tachycardias].
Topics: Administration, Oral; Adult; Aged; Cardiac Pacing, Artificial; Coronary Disease; Electrocardiography | 1987 |
[Effects of sotalol on action potentials of canine ventricular muscle fibers and Purkinje fibers in the postmyocardial infarction period].
Topics: Action Potentials; Animals; Dogs; Heart Conduction System; Myocardial Infarction; Myocardium; Purkin | 1986 |
[QT time and the ventricular refractory period in programmed electrical stimulation of the heart in patients with ventricular and supraventricular tachycardias--effect of sotalol].
Topics: Adult; Aged; Cardiac Pacing, Artificial; Cardiomyopathy, Dilated; Electrocardiography; Female; Heart | 1986 |
Contribution of delayed ventricular repolarization to the anti-arrhythmic efficacy of sotalol.
Topics: Animals; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Dogs; Dose-Response Relationship, Drug; | 1985 |
Heart-rate changes during movement of patients with acute myocardial infarction.
Topics: Adult; Aged; Atropine; Coronary Care Units; Depression, Chemical; Heart Rate; Humans; Middle Aged; M | 1974 |